Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2006-005218-11-IT
EUCTR2006-005218-11-IT
Active, not recruiting
Not Applicable

EFFECTIVENESS AND TOLERABILITY OF TREATMENT WITH CABERGOLINE IN PATIENTS WITH CUSHING S SYNDROME - CABERGOLINE IN CUSHING S SYNDROME

ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI0 sitesApril 3, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCushing syndromeMedDRA version: 9.1Level: LLTClassification code 10011652Term: Cushing's syndrome
DrugsDOSTINEXNIZORAL

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cushing syndrome
Sponsor
ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI
Status
Active, not recruiting
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 3, 2007
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI

Eligibility Criteria

Inclusion Criteria

  • •1 Age above 18 and below 65 years 2 Diagnosis of Cushing s syndrome due to pituitary or adrenal tumor or ectopic ACTH secretion, performed by the standard diagnostic procedures evaluation of urinary cortisol secretion, cortisol circadian rhythm,low\-dose and high\-dose dexamethasone test, CRH and/or DDAVP test 3 Documentation of baseline cortisol urinary levels at least two times higher and less than four times lower than the upper limit of normal range 4 Informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •1 Pregnancy or Lactation; 2 Documented intolerance to cabergoline; 3 Liver, renal or cardiovascular insufficiency; 4 Specific conditions and/or tumor characteristics which require an immediate alternmative treatment aggressivity of the neoplasm or sever organ compromission

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
A clinical study to evaluate the comparative efficacy of three Unani drugs in the treatment of Hepatitis B carriers
CTRI/2018/06/014642DG Central Council for Research in Unani Medicine
Not yet recruiting
Not Applicable
This study will investigate the anticancer effect and treatment-related safety when focused ultrasound stimuli is given for the pancreatic cancer in patients with unresectable pancreatic cancer who need chemotherapy in a prospective mannerNeoplasms
KCT0006302Seoul National University Hospital60
Not yet recruiting
Phase 3
Comparing collagen superabsorbent powder containing silver nanoparticles 15 ppm and 1% silver sulfadiazine ointmentBed Sore.
IRCT20230621058552N2Esfahan University of Medical Sciences68
Completed
Phase 2
The effect of phototherapy and oral Simvastatin in treatment of vitiligo
IRCT20150825023753N11Shiraz University of Medical Sciences50
Completed
Phase 3
A comparative study on the therapeutic effect of combined NBUVB and systemic Simvastatin with NBUVB alone in patients with vitiligo
IRCT20191013045092N2Shiraz University of Medical Sciences50